http://rdf.ncbi.nlm.nih.gov/pubchem/patent/RU-2706544-C1
Outgoing Links
Predicate | Object |
---|---|
assignee | http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_bb90618e7af0a61dfeb01fb3647f0ff6 |
classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K39-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N15-63 |
classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K39-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12N15-63 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12N5-02 |
filingDate | 2018-12-28-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
grantDate | 2019-11-19-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
inventor | http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_1cf98883aa104bd15bb80d3d758b7881 |
publicationDate | 2019-11-19-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
publicationNumber | RU-2706544-C1 |
titleOfInvention | Concentrate of influenza vaccine and method for its preparation |
abstract | FIELD: biotechnologies.SUBSTANCE: invention relates to the biotechnology. Described is a method for preparing a concentrate of a vaccine against influenza containing HPV, where haemagglutinin, neuraminidase and M1 protein genes are obtained from strain A/California/04/2009; haemagglutinin gene is obtained from strain A/Michigan/45/2015, and neuraminidase and M1 protein genes are obtained from strain A/California/04/2009; haemagglutinin gene is obtained from strain A/Novosibirsk/01/2014, and neuraminidase and M1 protein genes are obtained from strain A/California/04/2009; haemagglutinin gene is obtained from strain A/HongKong/4801/2014, and neuraminidase and M1 protein genes are obtained from strain A/California/04/2009; haemagglutinin gene is obtained from strain B/Phuket/3073/13, and neuraminidase and M1 protein genes are obtained from strain A/California/04/2009 or haemagglutinin gene is obtained from strain B/Brisbane/60/2008, and neuraminidase and M1 protein genes are obtained from strain A/California/04/2009. What is presented is an influenza vaccine concentrate containing one of said HPV types.EFFECT: invention enables to obtain HPV influenza virus having high haemagglutination activity; method also increases antigen output; besides, during the method implementation the viability and high productivity of the target proteins are preserved without the use of controlled expression in the HPV influenza cell-producing cells.4 cl, 44 dwg, 15 tbl, 7 ex |
priorityDate | 2018-12-28-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 524.